{"organizations": [], "uuid": "dbb29ed82d4cdb11f51c50ed411deda37bb74a02", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-presents-po/brief-ose-immunotherapeutics-presents-positive-ose-172-human-ex-vivo-and-preclinical-study-results-idUSFWN1R10VS", "country": "US", "domain_rank": 408, "title": "BRIEF-OSE Immunotherapeutics Presents Positive OSE-172 Human Ex-Vivo And Preclinical Study Results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T19:19:00.000+02:00", "replies_count": 0, "uuid": "dbb29ed82d4cdb11f51c50ed411deda37bb74a02"}, "author": "", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-presents-po/brief-ose-immunotherapeutics-presents-positive-ose-172-human-ex-vivo-and-preclinical-study-results-idUSFWN1R10VS", "ord_in_thread": 0, "title": "BRIEF-OSE Immunotherapeutics Presents Positive OSE-172 Human Ex-Vivo And Preclinical Study Results", "locations": [], "entities": {"persons": [{"name": "huma", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "american association for cancer research annual", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ose immunotherapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 5:19 PM / in 27 minutes BRIEF-OSE Immunotherapeutics Presents Positive OSE-172 Human Ex-Vivo And Preclinical Study Results Reuters Staff March 19 (Reuters) - OSE IMMUNOTHERAPEUTICS SA: * TO PRESENT NEW DATA ON OSE-172 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING * ‍OSE-172, SIRPA ANTAGONIST, PREVENTS METASTASIS SPREAD IN AGGRESSIVE CANCER MODELS​ * OSE-172 ‍DECREASES TUMOR GROWTH AND SUPPRESSIVE FUNCTION OF TUMOR MYELOID CELLS * ‍OSE-172 POTENTIATES DENDRITIC CELL TUMOR ANTIGEN CROSS-PRESENTATION INCREASING T-CELL SPECIFIC ACTIVATION​ * ‍DATA BEING PRESENTED ON OSE-172 INCLUDE RESULTS FROM HUMAN EX-VIVO AND PRECLINICAL STUDIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-03-19T19:19:00.000+02:00", "crawled": "2018-03-19T19:50:44.000+02:00", "highlightTitle": ""}